ARS Pharmaceuticals Inc (SPRY)
13.38
-0.17
(-1.25%)
USD |
NASDAQ |
Nov 21, 16:00
13.39
+0.01
(+0.07%)
After-Hours: 20:00
ARS Pharmaceuticals Revenue (Quarterly): 2.068M for Sept. 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | 2.068M |
| June 30, 2024 | 0.50M |
| March 31, 2024 | |
| December 31, 2023 | |
| September 30, 2023 | |
| June 30, 2023 | 0.01M |
| Date | Value |
|---|---|
| March 31, 2023 | 0.02M |
| December 31, 2022 | |
| September 30, 2022 | 0.189M |
| June 30, 2022 | 0.464M |
| March 31, 2022 | 0.663M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.01M
Minimum
Jun 2023
2.068M
Maximum
Sep 2024
0.5591M
Average
0.464M
Median
Jun 2022
Revenue (Quarterly) Benchmarks
| Exelixis Inc | 539.54M |
| Assembly Biosciences Inc | 6.845M |
| Protagonist Therapeutics Inc | 4.675M |
| Precision BioSciences Inc | 0.576M |
| Avidity Biosciences Inc | 2.336M |
Revenue (Quarterly) Related Metrics
| Net Income (Quarterly) | -19.13M |
| Total Expenses (Quarterly) | 23.82M |
| EPS Diluted (Quarterly) | -0.20 |
| Enterprise Value | 1.096B |
| Gross Profit Margin (Quarterly) | 94.58% |
| Profit Margin (Quarterly) | -925.0% |
| Earnings Yield | -3.81% |
| Normalized Earnings Yield | -3.812 |